Nicox

VYZULTA (Latanoprostene Bunod Ophthalmic Solution, 0.024%) – Reduces Intraocular Pressure for Glaucoma and Ocular Hypertension

VYZULTA is a unique ophthalmic solution designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This medication is the first prostaglandin analog to incorporate nitric oxide (NO) as one of its metabolites, providing a consistent and sustained reduction in IOP over 12 months.

How It Works

In glaucoma, damage to the trabecular meshwork can lead to reduced drainage of aqueous humor, causing elevated IOP. VYZULTA works by increasing the outflow of aqueous humor through both the trabecular meshwork and the uveoscleral pathways. This dual mechanism of action helps in reducing IOP, thereby delaying or preventing damage to the optic nerves and reducing the risk of glaucomatous visual field loss.

Key Features

• Nitric Oxide (NO) Metabolite: VYZULTA’s unique NO-donating mechanism enhances its efficacy in lowering IOP.
• Long-Term Efficacy: Clinically proven to reduce IOP consistently over 12 months.
• Dual Action: Increases outflow through both the trabecular meshwork and the uveoscleral pathways.
• Safety Profile: Well-established safety profile with minimal side effects, including increased pigmentation of the iris and eyelashes, and conjunctival hyperemia.

Important Safety Information

• Iris Pigmentation: Permanent changes to iris pigmentation may occur.
• Eyelash Changes: Gradual changes to eyelashes, including increased length and thickness, may occur. These changes are usually reversible upon treatment discontinuation.
• Common Adverse Reactions: Conjunctival hyperemia, eye irritation, eye pain, and instillation site pain.

About Nicox

Nicox is an international ophthalmic company dedicated to developing innovative solutions to maintain vision and improve ocular health. With a focus on nitric oxide-donating compounds, Nicox has developed an extensive portfolio of novel drug candidates targeting various ophthalmic conditions, including glaucoma. VYZULTA is one of their commercialized products, licensed worldwide to Bausch + Lomb, and is part of their ongoing efforts to provide effective treatments for glaucoma patients.

By using VYZULTA, patients can benefit from a reliable and sustained reduction in intraocular pressure, helping to protect their vision and prevent further damage to the optic nerves. If you have any questions or concerns about VYZULTA or any other ophthalmic condition, consult with your healthcare provider for personalized advice.